A synthetic biology research engine in South San Francisco. Sequence optimization, proprietary safety and targeting tools, and producer cell line engineering — all in service of getting your therapy to the clinic faster.
Our Genetic Design is where therapeutic candidates are conceived, optimized, and de-risked before they ever hit a bioreactor. We combine synthetic biology expertise, bioinformatics, and proprietary building blocks into a design environment built for the clinic.
Gene-of-interest, promoter, regulatory element, and payload architecture optimized across CAR/TCR-T, NK, Treg, and in-vivo gene therapy modalities.
Parallel evaluation of construct variants in primary and therapeutically relevant cell types — narrowing thousands of candidates to the few worth bringing into the clinic.
Bioinformatics analysis, protein and promoter library design, and AI-based protein design — sharpening which constructs make it into wet-lab screens.
Promoters designed for in-vivo cell therapy programs — driving expression in the target cell population, silent everywhere else.
Gene-expression switches optimized by directed evolution to respond to therapeutically relevant concentrations of FDA-approved small molecules with excellent pharmacological properties — giving clinicians dosable control of the engineered cell.
Selective elimination of engineered cells when needed — our system is optimized for rapid cell death, giving programs a robust safety lever that engages quickly when it's called for.
Over a dozen synthetic T-cell–specific promoters — validated for
T-cell specificity against diseases of B-cell dysregulation. Each is characterized for on-target strength and off-target silencing, so you
can pick the profile your program needs.
| Cell context | Benchmark |
GeneFab pT.14 |
GeneFab pT.30 |
|---|---|---|---|
| Primary T-cell on-target | 16% | 11% | 35% |
| Primary B-cell off-target | 1.1% | 0.04% | 0.8% |
| Liver (HUH7) off-target | 0.7% | 0.2% | 0.02% |
| HEK293T off-target | 0.02% | 0.03% | 0.02% |
Two representative promoters from the library shown against a benchmark competitor promoter. Full flow-cytometry panels and the complete promoter set are in the brochure.
The full set of capabilities that make up our integrated CDMO platform.
Adherent & suspension lentivirus — 2 L to 200 L GMP. Targeting and control built in.
Endotoxin, sterility, mycoplasma & identity testing — rapid and compendial, in-house.
Engineering, Master & Working cell banks. Adherent & suspension, run in parallel.
Knowledge transfer as a discipline. Development-to-GMP in ~7 months.
Dedicated PMO, transparent Gantts, real-time data exchange. One accountable team.
